» Articles » PMID: 23509897

Formal Hepatitis C Education Enhances HCV Care Coordination, Expedites HCV Treatment and Improves Antiviral Response

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2013 Mar 21
PMID 23509897
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Formal Hepatitis C virus (HCV) education improves HCV knowledge but the impact on treatment uptake and outcome is not well described. We aimed to evaluate the impact of formal HCV patient education on primary provider-specialist HCV comanagement and treatment.

Methods: Primary care providers within the San Francisco safety-net health care system were surveyed and the records of HCV-infected patients before and after institution of a formal HCV education class by liver specialty (2006-2011) were reviewed retrospectively.

Results: Characteristics of 118 patients who received anti-HCV therapy were: mean age 51, 73% males and ~50% White and uninsured. The time to initiation of HCV treatment was shorter among those who received formal education (median 136 vs 284 days, P < 0.0001). When controlling for age, gender, race and HCV viral load, non-1 genotype (OR 6.17, 95% CI 2.3-12.7, P = 0.0003) and receipt of HCV education (OR 3.0, 95% CI 1.1-7.9, P = 0.03) were associated with sustained virologic treatment response. Among 94 provider respondents (response rate = 38%), mean age was 42, 62% were White, and 63% female. Most providers agreed that the HCV education class increased patients' HCV knowledge (70%), interest in HCV treatment (52%), and provider-patient communication (56%). A positive provider attitude (Coef 1.5, 95% CI 0.1-2.9 percent, P = 0.039) was independently associated with referral rate to education class.

Conclusions: Formal HCV education expedites HCV therapy and improves virologic response rates. As primary care provider attitude plays a significant role in referral to HCV education class, improving provider knowledge will likely enhance access to HCV specialty services in the vulnerable population.

Citing Articles

Steatotic Liver Disease Education Enhances Knowledge and Confidence to Adhere to Provider Recommendations in Diverse and Vulnerable Populations.

Patel S, Partida D, Magee C, Garza Romero F, Chen J, Tana M Gastro Hep Adv. 2025; 4(3):100589.

PMID: 39931048 PMC: 11808611. DOI: 10.1016/j.gastha.2024.11.005.


Rapid point-of-care testing for hepatitis C - assessment of feasibility, knowledge of participants and outcomes.

Khan A, Tarr A, Berahmana A, Johnson E, Schultz M, Johnson S Gastroenterol Hepatol Bed Bench. 2024; 17(3):260-269.

PMID: 39308536 PMC: 11413387. DOI: 10.22037/ghfbb.v17i3.2989.


Exploring the Perspectives of Unhoused Adults and Providers Across the HCV Care Continuum.

Salem B, Almeida H, Wall S, Yadav K, Chang A, Gelberg L Clin Nurs Res. 2024; 33(7):519-529.

PMID: 39246038 PMC: 11421191. DOI: 10.1177/10547738241273104.


HEPATITIS C PSYCHOEDUCATION CURRICULUM TOPICS GENERATED BY GROUP MEMBERS.

Pollio D, North C, Sims O, Hong B Soc Work Groups. 2024; 44(1):83-90.

PMID: 38274393 PMC: 10810246. DOI: 10.1080/01609513.2020.1815631.


Care for Vulnerable Populations with Chronic Liver Disease: A Safety-Net Perspective.

Wang M, Bangaru S, Zhou K Healthcare (Basel). 2023; 11(20).

PMID: 37893800 PMC: 10606794. DOI: 10.3390/healthcare11202725.


References
1.
Morrill J, Shrestha M, Grant R . Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005; 20(8):754-8. PMC: 1490173. DOI: 10.1111/j.1525-1497.2005.0161.x. View

2.
Rodis J, Kibbe P . Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010; 33(5):368-73. DOI: 10.1097/SGA.0b013e3181f443cb. View

3.
Chen A, Yee Jr H . Improving the primary care-specialty care interface: getting from here to there. Arch Intern Med. 2009; 169(11):1024-6. DOI: 10.1001/archinternmed.2009.140. View

4.
Canfield K, Smyth E, Batki S . Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse. 2010; 45(4):496-514. DOI: 10.3109/10826080903452538. View

5.
Mitchell A, Colvin H, Beasley R . Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010; 51(3):729-33. DOI: 10.1002/hep.23561. View